 HAYWARD, Calif., April 27, 2021 PRNewswire -- Benitec Biopharma Inc. NASDAQ: BNTC Benitec or the Company, a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ddRNAi platform, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,036,366 shares of common stock of the Company at a price to the public of 4.25 per share, less underwriting discounts and commissions. 